Biotech Jonathan Wosen STAT Plus: Upstart Element ratchets up race for cheaper DNA sequencing with a $200 genome
Biotech Jason Mast STAT Plus: Still hoping for looser FDA rules, Regeneron says it will test durable antibody for Covid
Pharma Kate Sheridan STAT Plus: People hate drug ads on TV. Here’s the 4 issues they complain about most
Biotech Jonathan Wosen STAT Plus: FDA’s Califf says congressional report on Aduhelm controversy contained ‘no surprises’
Biotech Adam Feuerstein STAT Plus: New Biogen CEO: New drug launches, more cost cuts, but no ‘radical left turns’ needed
Biotech Jonathan Wosen and Allison DeAngelis STAT Plus: A flurry of pharma acquisitions kick off JPM week after a slow year for deals
Biotech Adam Feuerstein STAT Plus: Arrowhead RNA treatment improves liver scarring in patients, but so does a placebo, clouding study results
Biotech Matthew Herper STAT Plus: BioMarin executives express confidence around hemophilia gene therapy
Exclusive Jason Mast STAT Plus: Day One says drug shrinks tumors in common pediatric brain cancer, setting up potential approval
Biotech Adam Feuerstein and Allison DeAngelis STAT Plus: Money troubles and M&A: What’s on biotech insiders’ minds ahead of a not-so-celebratory JPM week
Biotech Adam Feuerstein STAT Plus: FDA approves Alzheimer’s drug shown to moderately slow cognitive decline in early stages of the disease
Biotech Jonathan Wosen STAT Plus: Fate Therapeutics plans mass layoffs, after early end to cell therapy deal with Janssen
Biotech Allison DeAngelis STAT Plus: Biogen shakes up R&D chief role, makes Singhal permanent replacement
Biotech Jason Mast STAT Plus: As FDA considers new Alzheimer’s drug, a case study details safety concerns
Biotech Allison DeAngelis STAT Plus: Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study
Biotech Jason Mast STAT Plus: Geron, biotech that once sparked talk of immortality, finally gets a (more modest) success
Biotech Adam Feuerstein STAT Plus: The biotech scorecard for the first quarter: 19 stock-moving events to watch
The Aduhelm Files Damian Garde and Rachel Cohrs STAT Plus: In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments
The Aduhelm Files Rachel Cohrs, Adam Feuerstein and Damian Garde STAT Plus: FDA, Biogen, and an Alzheimer’s drug approval: 8 key takeaways from congressional investigation
The Aduhelm Files Rachel Cohrs STAT Plus: ‘Rife with irregularities’: Congressional investigation reveals FDA’s approval of Aduhelm marked by secret discussions, breaches of protocol
The Aduhelm Files Damian Garde and Adam Feuerstein STAT Plus: Seeking maximum profits, Biogen set an ‘unjustifiably high price’ for Alzheimer’s treatment, investigation finds
Biotech Damian Garde STAT Plus: Get ready for ‘the electric vehicles of biopharma’: Three biotech trends to watch in 2023
Biotech Damian Garde STAT Plus: Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Biotech Brittany Trang STAT Plus: Gene therapy trial shows promise for treating ‘bubble boy’ syndrome. Now comes the hard part
Biotech Allison DeAngelis STAT Plus: Young private equity firm Catalio to absorb hedge fund HealthCor, capping off busy year of investment M&A